A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor

May 27, 2026 updated by: Shenzhen Ionova Life Sciences Co., Ltd.

A Phase 1 and Phase 2, First-in-Human, Multi-Center, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor

This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-6452 in adult patients with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) advanced/metastatic breast cancer or locally advanced/metastatic solid tumor.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

201

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China
        • Recruiting
        • Fudan University Shanghai Cancer Center
        • Principal Investigator:
          • Jian Zhang, MD
        • Contact:
        • Principal Investigator:
          • Jiong Wu, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Written informed consent obtained.
  2. Adult patients aged ≥ 18 years.
  3. Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors, who have disease progression following standard-of-care therapy, are intolerant to standard treatment, or have no available standard treatment options (e.g., HR+/HER2- breast cancer, Cyclin E1-overexpressing solid tumors and other solid tumors).
  4. Agree to provide available archived FFPE tumor tissue specimens or voluntarily accept pre-treatment tumor biopsy (Phase Ⅱ).
  5. Have RECIST 1.1-defined measurable lesions.
  6. Has a life expectancy of > 3 months.
  7. ECOG performance status 0-1.
  8. Adequate marrow, liver and kidney function.
  9. Meet the study's specified contraceptive requirements.

Exclusion Criteria:

  1. Have a second primary malignancy.
  2. Patients with primary CNS tumors or CNS metastases with prior local treatment failure.
  3. Have received any anti-tumor therapy or participated in other therapeutic clinical trial within 28 days prior to the first dose of study drug.
  4. Has undergone major surgery within 28 days prior to the first dose of study drug.
  5. Prior anti-tumor therapy-related toxicities have not recovered to protocol-specified grades.
  6. Diagnosed with immunodeficiency or received any form of immunosuppressive therapy within 7 days prior to the first dose.
  7. Patients with other severe and persistent underlying medical conditions as assessed by the Investigator.
  8. Have protocol-defined clinically significant cardiovascular diseases.
  9. Prolonged QTcF interval.
  10. Have any medical conditions likely to impair digestion and absorption of the investigational product.
  11. Patients with poorly managed blood glucose levels and blood pressure.
  12. Clinically significant abnormal serum potassium or sodium as judged by the investigator.
  13. Have experienced a severe concurrent infection 14 days prior to the first dose of study drug.
  14. Confirmed infection with HIV, HBV or HCV.
  15. Are currently receiving any other investigation agent.
  16. Have received prior CDK2 inhibitors.
  17. Patients with known hypersensitivity to the study drug or any of its components.
  18. History of allogenic tissue or solid organ transplant.
  19. Are unwilling or unable to comply with procedures required in this protocol.
  20. Has other severe systemic diseases or for other reasons deemed ineligible for participation in this clinical trial by the investigator.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Phase 1 INV-6452 Dose escalation
Drug: INV-6452
once daily orally
Experimental: Phase 2 INV-6452 Dose expansion
Drug: INV-6452
once daily orally

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Phase 1: Maximum tolerated dose (MTD)
Time Frame: Within first 28 days of treatment
The highest dose level at which at least 6 patients have been treated and less than 33% of patients experienced a DLT.
Within first 28 days of treatment
Phase 1: Recommended dose range (RDR)
Time Frame: 12 months
The RDR will be determined based on the PK and PD data, the preliminary clinical activity of INV-6452, as well as the incidence rate and nature of the toxicities observed in subsequent cycles beyond Cycle 1.
12 months
Phase 2: Evaluate overall response rate (ORR)
Time Frame: 12 months
The RDR will be determined based on the PK and PD data, the preliminary clinical activity of INV-6452, as well as the incidence rate and nature of the toxicities observed in subsequent cycles beyond Cycle 1.
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Phase 1: Determine the pharmacokinetics (PK) using AUC of INV-6452
Time Frame: 12 months for Phase 1
To determine the PK using AUC of INV-6452 after a single dose and at steady state after multiple doses for Phase 1
12 months for Phase 1
Phase 2: Determine the PK using AUC of INV-6452
Time Frame: 12 months for Phase 2
To determine the PK using AUC of INV-6452 after a single dose and at steady state after multiple doses for Phase 2
12 months for Phase 2

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Shenzhen Ionova Life Sciences Co., Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 4, 2025

Primary Completion (Estimated)

February 4, 2028

Study Completion (Estimated)

February 4, 2028

Study Registration Dates

First Submitted

May 21, 2026

First Submitted That Met QC Criteria

May 27, 2026

First Posted (Actual)

May 29, 2026

Study Record Updates

Last Update Posted (Actual)

May 29, 2026

Last Update Submitted That Met QC Criteria

May 27, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • INV-6452-101

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ovarian Cancer

Clinical Trials on INV-6452

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe